We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MICROSENS TEST DETECTS CJD IN PATIENT'S SERUM.
- Abstract
British diagnostics company, Microsens SA said on May 26, 2004, that it had won the race to detect abnormal prion proteins in the blood of patients with suspected Creutzfeldt-Jakob disease (CJD). The London-based private equity company presented findings of this report at the NeuroPrion Conference in Paris, France. Microsens has developed a ligand-based technology, called Seprion, into a simple immunoassay. It is reported that an affinity ligand captures the abnormal protein, an antibody detects it, and an enzyme signals the positive result by turning the sample blue. The technology was used to compare blood samples from a human patient with symptoms associated with CJD to control samples.
- Subjects
CREUTZFELDT-Jakob disease; PRION diseases; CLINICAL pathology; MICROSENS SA; MEDICAL research; LIGAND binding (Biochemistry); ANALYTICAL biochemistry
- Publication
Clinical Infectious Diseases, 2004, Vol 39, Issue 2, piii
- ISSN
1058-4838
- Publication type
Article